CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- 4 Grant or award See Remarks acquired 23,116 shares (grant or award)
- 4 Grant or award See Remarks acquired 23,116 shares (grant or award)
- 4 Grant or award EVP and Chief Legal Officer acquired 28,895 shares (grant or award)
- 4 Grant or award EVP & Chief Commercial Officer acquired 28,895 shares (grant or award)
- 4 Grant or award EVP and Chief Medical Officer acquired 34,674 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 34,674 shares (grant or award)
- 4 Planned sale Chief Financial Officer sold 4,683 shares at $20.97 ($98,203)
- 4 Open-market sale EVP and Chief Legal Officer sold 9,526 shares at an average $21.87 ($208,312)
- 4 Open-market sale See Remarks sold 10,029 shares at $22.80 ($228,661)
- 4 Open-market sale EVP & Chief Commercial Officer sold 10,539 shares at $22.80 ($240,289)
- 4 Open-market sale President & CEO sold 54,404 shares at $22.80 ($1,240,411)
- 4 Open-market sale EVP and Chief Legal Officer sold 8,135 shares at $22.80 ($185,478)
- 4 Open-market sale SVP, Chief Accounting Officer sold 1,632 shares at $22.80 ($37,210)
- 4 Planned sale Chief Financial Officer sold 10,044 shares at an average $22.65 ($227,538)
- 4 Open-market sale EVP and Chief Medical Officer sold 7,029 shares at $22.80 ($160,261)
- 4 Shares withheld for taxes See Remarks gave up 999 shares (to pay taxes)
- 4 Planned sale Chief Financial Officer sold 3,061 shares at $23.56 ($72,117)
- 4 Planned sale Chief Financial Officer sold 3,150 shares at $22.84 ($71,946)
- 4 Open-market sale SVP, Chief Accounting Officer sold 85 shares at $34.38 ($2,922)
- 4 Planned sale Chief Financial Officer sold 3,081 shares at $36.38 ($112,087)
Page 2 of 32 · 627 filings